Dave Lemus

Dave Lemus is an experienced C-Level executive (CEO-COO-CFO) and Non-Executive board member with extensive US & international business experience spanning over 20 years biotech in the biopharmaceutical industry, where he executed more than $3 billion in licensing, financing/capital markets and M&A transactions.

Mr. Lemus is currently CEO of LEMAX LLC, a strategic advisory service he founded focused on the biotech and pharmaceutical industries. Additionally he also serves as a non-executive director on the boards of Sorrento Therapeutics (NASDAQ: SRNE), Silence Therapeutics plc (AIM: SLN), Celularity Inc., and the MIT Club Washington DC. Previously he was CEO of Sigma Tau Pharmaceuticals Inc., and prior to this, CFO of MorphoSys AG, where he launched Germany’s first biotechnology IPO in 1999, having come from Hoffmann La Roche in Basel.

He received his M.S. from the Massachusetts Institute of Technology, and B.S. from the University of Maryland, and is presently a C.P.A. in the state of Maryland.